Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

RYGB tops sleeve gastrectomy in long-term outcomes for diabetes

Key clinical point: Patients with type 2 diabetes who had Roux-en-Y gastric bypass had better outcomes in weight loss, disease remission and relapse, and glycemic control, compared with those who had sleeve gastrectomy.

Major finding: The estimated cumulative diabetes remission rate 5 years after surgery, was 86% for Roux-en-Y gastric bypass and 84% for sleeve gastrectomy.

Study details: A cohort study with 9,710 adults with type 2 diabetes, who had bariatric surgery between Jan. 1, 2005, and Sept. 30, 2015.

Disclosures: The study was conducted using the National Patient-Centered Clinical Research Network, which was funded by the Patient-Centered Outcomes Research Institute. Dr. McTigue and Dr. Liu had reported no conflicts of interest. Dr. Funk disclosed a Veterans Affairs Health Services Research & Development Career Development Award, and grants from the VA, National Institutes of Health, and American College of Surgeons.


McTigue KM et al. JAMA Surg. 2020 Mar 4. doi: 10.1001/jamasurg.2020.0087; Lui N, Funk LM. JAMA Surg. 2020 Mar 4. doi: 10.1001/jamasurg.2020.0088.